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A recombinant  human  prothrombin  was  prepared  in 
which  Arg166  was  replaced  by  Ala.  The  recombinant  pro- 
thrombin  was  converted  into a meizothrombin  deriva- 
tive (R155A meizothrombin)  that  was  resistant  to  auto- 
catalytic removal of the fragment 1 domain. R156A 
meizothrombin  appeared  to  be a  potent  factor V activa- 
tor in reaction  mixtures  that  contained  negatively 
charged  phospholipid  vesicles.  Factor V activation by 
R155A meizothrombin was characterized by second- 
order  rate  constants  of 0.06 x 10' "' 8-l in  the  absence  of 
phospholipid  and 18 x 10' M - ~  s-l in the  presence  of 60 p~ 
phospholipid  vesicles  composed  of a 1090 mol/mol  mix- 
ture of phosphatidylserine (PS) and phosphatidylcho- 
line  (PC). The rate  constant  for  thrombin-catalyzed  ac- 
tivation of  factor V was  hardly  affected  by  the  presence 
of  phospholipid vesicles and was 4.0 x 10' M - ~  s-l. The 
initial  rate of activation of 3 n~ factor V by R155Ameizo- 
thrombin  was a  function of  the  concentration  of  PSPC 
vesicles  present in the  reaction  mixture,  and  the  calcu- 
lated  rate  constant  reached  a  plateau  value  at 250 p~ 
PSPC. Gel  electrophoretic  analysis  of  factor V activa- 
tion  showed  that R155A meizothrombin  and  thrombin 
cleaved  the  susceptible  peptide  bonds  in  factor V at dif- 
ferent  rates.  However,  both  activators  finally  generated 
a  factor Va molecule  composed  of a heavy  chain  with  an 
M, of 104,000 and a  light  chain  doublet  with M, values  of 
74,000 and 71,000. Since meizothrombin is one of the 
major reaction  products  formed  during  the  initial  phase 
of  prothrombin  activation,  these  findings  are  indicative 
of a  significant  contribution f  meizothrombin  to in vivo 
factor V activation. 
Human blood coagulation factor V is a single chain glyco- 
protein  (1,  2)  that, during hemostasis,  is  converted  into  factor 
Va via  limited  proteolysis  by enzymes (e.g. thrombin and factor 
Xa) generated after  the  initiation of blood coagulation (1-6). 
Factor Va is the nonenzymatic cofactor of the prothrombin- 
activating  complex,  which  also  comprises the serine  protease 
factor  Xa,  calcium  ions,  and a procoagulant  membrane  surface. 
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Depending on the reaction conditions, factor Va accelerates 
prothrombin  activation 103-105-fold (7-9). 
The important  function of factor Va in hemostatic  plug for- 
mation is further  underscored  by  the  observation  that,  during 
in  vitro coagulation, factor Va is the rate-limiting factor in 
prothrombin  activation  (10) and by  the  fact hat the activity of 
factor Va is efficiently  regulated  by  activated  protein C (11). 
Since  factor V is unable to act as a cofactor in the prothrombi- 
nase complex (7), activation of factor V must  be a key  event  in 
thrombin  formation. 
Here  we  report hat meizothrombin, a reaction  intermediate 
that accumulates  during the initial  phase of prothrombin  acti- 
vation (12-15), may be an important  factor V activator. Meizo- 
thrombin  exhibits  full  activity  on  chromogenic  substrates, but 
compared  with  thrombin, it has a reduced  activity  on  macro- 
molecular  protein  substrates (12,  16). Studies on the catalytic 
activities of meizothrombin are hampered,  however,  by the fact 
that it is autoproteolyzed  to  meizothrombin(desF1)'  (12,  17) or 
thrombin  (17). In this paper,  we  describe the preparation of a 
recombinant  human  prothrombin whichArg'55 is replaced  by 
Ala. The  recombinant  prothrombin  was  converted  into meizo- 
thrombin,  which,  due  to the amino  acid  substitution,  could  not 
be converted  to  meizothrombin(desF1) and which  was  not  meas- 
urably  autolyzed  to  thrombin. This meizothrombin  derivative 
is a powerful  factor V activator  in the presence of phospholip- 
ids.  Since its activity  can  even  exceed that of thrombin,  activa- 
tion of factor V by  meizothrombin  may  be of prime  importance 
for the initiation of prothrombin  activation. 
EXPERIMENTAL PROCEDURES 
Materials-Ovalbumin, BSA,  bovine brain PS, and egg  yolk  PC  were 
purchased from Sigma. DOPC and DOPS  were obtained from  Avanti 
Polar Lipids, Inc. (Pelham, AL). Small unilamellar phospholipid 
vesicles  were prepared as described  before (18). S2238  (D-Phe-pipecolyl- 
Arg p-nitroanilide) and I2581 (N-dansyl-(p-guanidin0)phenylalanine 
piperidide hydrochloride) were supplied by Chromogenix. Materials 
used for protein purification were purchased from Pharmacia Biotech 
Inc. The adenovirus-transformed human kidney 293 cell line (ATCC 
CRL1573) was from Flow Laboratories, Inc. Escherichia coli 1061P3 
and plasmid pcDNAl were from Invitrogen. Iscove's and Optimeml 
media were from Life Technologies, Inc. Vitamin K, was from Hoff- 
mann-La Roche. Human coagulation factors were prepared by earlier 
described procedures (14, 18). The prothrombin activator from Echis 
coloratus was purified from the crude venom (Latoxan) by  gel perme- 
ation chromatography on Superdex 200 and ion-exchange  chromatog- 
raphy on  Mono Q and Mono S. The venom prothrombin activator was 
applied to a Mono Q column in 50 mM Tris (pH 7.9),  100 mM NaCl, 0.1 
mM CaCl, and to a Mono S column in 25 mM Hepes (pH 7.7), 50 mM 
NaCl, 0.1 mM CaC1, and eluted from the columns at NaCl concentra- 
tions between  150 and 200 mM. Details of the purification procedure will 
be described elsewhere.2 
Cloning of Prothrombin and Construction of R155A Prothrombin- 
Full-length prothrombin cDNA was obtained as described  before (19). 
Mutagenesis was performed by the polymerase chain reaction overlap 
extension technique (20) using two overlapping oligonucleotides (5'- 
CGATGACTCCAWTCCGAAGGCTCC-3' and 5'-GGAGCCTTCG- 
GAmTGGAGTCATCG-3'  (mutated sequence is underlined)), result- 
ing  in  the replacement of Arg155 with Ala. The mutated fragment was 
used to substitute the wild-typeXhoI-BstEII fragment of prothrombin in 
pcDNAl, and the DNA sequence was  confirmed  for the  entire fragment. 
The abbreviations used are: F1, prothrombin fragment 1; BSA,  bo- 
vine serum albumin; PS, phosphatidylserine; PC, phosphatidylcholine; 
DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPS,  1,2-dioleoyl- 
sn-glycero-3-phosphoserine; dansyl, 5-dimethylaminonaphthalene-l- 
sulfonyl; PAGE, polyacrylamide  gel electrophoresis. 
G. A.  F. Nicolaes, G. Tans, and J. Rosing, manuscript in preparation. 
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FIG. 1. Gel electrophoretic analysis of Rl55Aprothrombin and 
R155A meizothrombin. R155A prothrombin  (2.64 p ~ )  was  incubated 
a t  37 "C with 65 ng/ml purified  prothrombin  activator from E. coloratus 
venom in a reaction  mixture  containing  25 mM Hepes  (pH 7.5), 175 mM 
NaCI, 5 mM CaCI,, and 20 p~ 12581. After 4  min, the activation  mixture 
was  applied  to a Mono S HR5/5 column equilibrated  with  25 mM Hepes 
(pH  7.7)  and  50 mM NaCl. R155A meizothrombin  passed  through this 
column, and  I2581  was  added to the meizothrombin-containing frac- 
tions to a final concentration of 20 PM. The R155A meizothrombin 
preparation  was  stored at -80 "C. The gel represents SDS-PAGE anal- 
ysis of R155A prothrombin  (lane 1 ), R155A meizothrombin  (lane 2), 
molecular weight standards  (lane 3), R155A prothrombin + 5% p-mer- 
captoethanol  (lane 4) ,  and R155A meizothrombin + 5% P-mercaptoeth- 
anol  (lane 5). 
Expression of Recombinant Prothrombin-The prothrombin cDNAs 
obtained from the pcDNAl  plasmid by digestion  with EcoRI and  XbaI 
were  inserted  into  the  BclI  site of expression vector p-GTh (a gift of Dr. 
B. W. Grinnell, Lilly). This  vector  enables  high  expression  levels in  the 
adenovirus-transformed human kidney 293 cell line and selection of 
positive clones with hygromycin B since the vector contains  the  cistron 
for expression of hygromycin phosphotransferase. 
Cells  were grown in  Optimeml medium  supplemented  with 5% fetal 
calf serum  and  10  pg/ml  vitamin K,. The cells were  transfected,  and 
colonies were  selected as described by Walls et al. (21). The  selected cell 
line  was grown in 175-cm2 culture  dishes  in  the  medium  described abov . 
After  reaching confluency, the cells were  kept  serum-free in  Optimeml 
medium  with  10 pg/ml vitamin K,, and  the medium  was collected and 
refreshed  each  72  h for 8 weeks.  The  medium  was  centrifuged for 20  min 
at 14,000 x g, and  the  supernatant  was  stored a t  -80  "C. 
Purification and Characterization of R155A Prothrombin-In a typi- 
cal  purification,  0.5  liter of medium (to which  0.5 mg/ml ovalbumin  was 
added  to minimize protein  losses  during  the first purification  step)  was 
loaded a t  4 "C on a 5-ml fast flow Q-Sepharose column. The column was 
washed  with  100 ml of 50 mM Tris (pH 7.5 a t  4 "C) and 150 mM NaCI, 
and R155A prothrombin  was  eluted  with  a 100-ml linear  gradient of 
150-1000 mM NaCl in  the  same buffer. R155A prothrombin-containing 
fractions  were pooled and diluted 5-fold in 50 mM Tris (pH 7.5 a t  20 "C) 
and applied to a Mono Q column (HR 5/5). R155A prothrombin was 
eluted  with a 30-ml linear  gradient of 100-1000 mM NaCl in  the  same 
buffer. R155A prothrombin-containing  fractions  were pooled, dialyzed 
against  25 mM Hepes  (pH  7.5)  and  175 mM NaCl a t  4 "C, and  stored at 
-80 "C. R155A prothrombin  appeared as  a closely spaced  doublet on 
nonreduced  gels and  as a single  smeared  band on reduced  gels (Fig. 1). 
R155A prothrombin was fully carboxylated as determined by the 
method of Kuwada  and  Katayama (22). Concentrations of R155A pro- 
thrombin  were  determined after complete activation  with  Echis  cari- 
natus venom and by enzyme-linked  immunosorbent  assay  using a bi- 
otinylated  rabbit polyclonal antibody  to  human  prothrombin.  Antigen/ 
activity  ratios,  initial rates of activation by the  prothrombinase 
complex, and final  levels of thrombin  obtained  were  the  same for R155A 
prothrombin and purified human  plasma  prothrombin. 
Protein Concentrations-R155A meizothrombin  concentrations  were 
determined  with  S2238,  considering  that  the  amidolytic activity/mole of 
R155A meizothrombin is  the  same as that of thrombin (12, 16). 
Factor Va was  quantitated by determining  the  rate of factor  Xa-cata- 
lyzed prothrombin  activation  in  reaction  mixtures  that  contained a lim- 
iting  amount of factor Va and  saturating concentrations of phospholipid 
vesicles (50 PM PSPC, 10:90 mol/mol), factor Xa (5 nM), and  prothrombin 
(0.5 PM) (18).  The  inhibitor  I2581 (20 JIM) was  present o prevent  further 
activation of factor  V by thrombin  generated  in  the  assay  mixture.  I2581 
did  not  interfere  with  the  subsequent  thrombin  determination  since  it  is 
a  reversible  inhibitor whose inhibitory  action in  the  thrombin  assay  was 
A B 
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meizothrombin, and meizothrombin(desF1). Human  factor  V (3 
FIG. 2. Time courses of factor V activation by  thrombin,  R155A 
nM) was  activated a t  37 "C with 0.15 nM thrombin (O), R155A meizo- 
thrombin (01, or meizothrombin(desF1) (A) in  the absence (A) or pres- 
ence ( B )  of 60 p~ DOPS/DOPC (10:90 mol/mol) vesicles in  a reaction 
mixture  containing  25 mM Hepes  (pH 7.5), 175 mM NaCI, 5 mM CaCl,, 
and 5 mg/ml BSA. After the  time  intervals  indicated,  aliquots from the 
activation  mixture  were  assayed for the presence of factor Va as de- 
scribed  under  "Experimental Procedures." 
essentially  eliminated by dilution  and by the presence of 532238. The 
factor Va molar  concentration  was  calculated from the  rate of prothrom- 
bin  activation  using a turnover  number of 6000 mol  of prothrombin ac- 
tivated  per  midmol of factor Xa-Va complex (14). 
RESULTS 
Preparation of R155A Meizothrombin"R155A  prothrombin 
was converted into R155A meizothrombin with the purified 
prothrombin  activator from E. coloratus venom. R155A meizo- 
thrombin  was  separated from the venom activator on a Mono S 
column. This column material did not bind R155A meizothrom- 
bin,  but  retained  the venom activator.  Immediately after elu- 
tion of R155A meizothrombin, the  thrombin  inhibitor I2581 
(final concentration of 20 p ~ )  was  added  to  prevent  autocata- 
lytic  peptide bond cleavages. SDS-PAGE analysis of R155Apro- 
thrombin  and of the R155Ameizothrombin that  eluted from the 
Mono S column showed that R155A prothrombin was com- 
pletely  converted into R155A meizothrombin and  that no fur- 
ther peptide bond cleavages had occurred. R155A meizothrom- 
bin  was  stored at -80 "C. Before use,  I2581  was removed by 
passage  through a prepacked Sephadex G-25 PD-10 column. 
The meizothrombin preparation  thus  obtained  was  diluted  to 
50 nM and  was  stable for at least  12 h at 0 "C. 
Activation of Factor V by R155A Meizothrombin, Meizo- 
thrornbin(desFl), and Thrombin-Time courses of factor  V ac- 
tivation by R155A meizothrombin, meizothrombin(desFl),  and 
thrombin  are  presented  in Fig. 2. In  free solution, R155Ameizo- 
thrombin  and meizothrombin(desF1)  were poor factor  V  acti- 
vators, with activities that were <5% of that of thrombin (Fig. 
2A) .  However, when negatively  charged phospholipid vesicles 
were included in the activation mixture,  there  was a drastic 
increase  in  the  rate of R155A meizothrombin-catalyzed  activa- 
tion of factor V, while there  was  hardly  any effect on  factor V 
activation by thrombin or meizothrombin(desF1) (Fig. 2 B ) .  We 
verified that factor  V activation  in reaction mixtures containing 
phospholipids and R155A meizothrombin was not due  to 
a-thrombin formed by autoproteolysis of R155A meizothrom- 
bin. This is concluded from the  fact  that R155A meizothrombin 
present  in  activation  mixtures  retained full  amidolytic  activity 
when incubated  with  antithrombin I11 + heparin, which shows 
that it is not converted into  a-thrombin since this would be 
readily  inhibited by these  inhibitors (12). 
Initial  rates of factor Va generation were linear  in  time be- 
tween 0 and 3 min  and directly  proportional to  the concentra- 
tions of factor  V (0-5 nM) and  activator (0-0.3 nM) present  in  the 
reaction  mixture  (data  not shown). This shows that factor  V 
activation under  these conditions is first-order in both  factor  V 
nd  activator (R155A meizothrombin, meizothrombiddesFl), 
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TABLE I
Second-order  rate  constants for factor V activation 
Rate constants for factor V activation by thrombin meizothrom- 
bin(desFl), or R155A meizothrombin  were  calculated from the  initial 
rates of factor Va formation  obtained from the  time  courses of factor  V 
activation  presented  in  Fig.  2. 
Factor V activator 
k 
No lipid +60 PM DOPSDOPC 
M - I  S-I 
Thrombin 4.0 x IO' 3.6 x 10' 
Meizothrombin(desF1) 0.17 x 10' 0.22 x 10' 
R155A meizothrombin 0.06 x 10' 18 x 10' 
0 50 100 150 200 
Phospholipid (pM) 
FIG. 3. Phospholipid dependence of R155A meizothrombin- 
catalyzed  activation  of  factor V. Human  factor  V (3 nM) was  acti- 
vated at 37 "C with 0.03 nM R155Ameizothrombin  in a reaction  mixture 
containing  25 mM Hepes  (pH  7.5),  175 mM NaC1, 5 mM CaCI,, 5 mg/ml 
BSA, and  the  indicated  concentrations of DOPSVDOPC (10:90 mol/mol) 
vesicles. After  appropriate  time  intervals,  aliquots  were  taken from the 
activation mixture and assayed for the presence of factor Va as  de- 
scribed  under  "Experimental  Procedures."  Initial  rates of factor  V  acti- 
vation  were  obtained from the  time  courses of factor Va formation by 
linear  regression. 
or  thrombin), which  allows the calculation of second-order rate 
constants for  factor  V activation from the  initial  rates of factor 
Va formation.  These  rate  constants  are  summarized  in Table I. 
Thrombin catalyzed  factor  V activation  with second-order rate 
constants of 4.0 x lo6 M-' s" in  the  absence of phospholipid 
vesicles and 3.6 x lo6 M-' s-' in  their presence. The  rate con- 
stant for meizothrombin(desF1)-catalyzed factor  V activation 
was -20-fold lower (k = 0.17 x lo6 M-' s-') and  was  also  hardly 
affected by the presence of phospholipid. In free solution, 
R155A meizothrombin was  the  weakest factor  V activator (k = 
0.06 x 10' M-' s-'1. However, the  presence of 60 VM PSffC (10:90 
mol/mol) vesicles caused a 300-fold increase  in  the  initial  rate of 
R155A meizothrombin-catalyzed  factor  V activation, yielding a 
rate  constant (k = 18 x 10' M" s-l) that even exceeds that of 
thrombin. 
The  initial  rate of factor  V activation by R155A meizothrom- 
bin was a function of the phospholipid concentration  in  the 
reaction  mixture.  The  rate  constant  calculated from the  initial 
phase of time  courses of activation of 3 nM factor  V by R155A 
meizothrombin increased from 0.06 x 10' M-' s-' in  the absence 
of phospholipid vesicles to  an  average  plateau  value of 19 x lo6 
M-' s-' at PSffC (10:90 mol/mol) vesicle concentrations of 250 
p~ (Fig. 3). Half-maximal rates of factor V activation were 
observed at -10 p~ PSffC. 
A remark is due  here  regarding  the  equation that describes 
time courses of factor  V activation  such as those  presented  in 
Fig. 2. Theoretically, the  time  course of product generation of an 
enzyme-catalyzed reaction  determined  under pseudo first- 
order conditions is described by the  equation P, = So(l - e-k.'), in 
which P, is  the  product  concentration a t  time t ,  So is  the  sub- 
strate  concentration a t  t = 0, and k is  the pseudo first-order  rate 
constant of the reaction. The second-order rate  constant of the 
reaction  is  obtained  after dividing the pseudo first-order  rate 
constant by the enzyme concentration. The time courses of 
thrombin-catalyzed  factor  V activation could be fitted  with  this 
(A) Thrombin 
- - -  " _  , I '  ' -" 
1 hFV 
- 280,000 
200,000 b 
'220,000 
116,500 b - HC 
97,400 b 
66,200 b 
45,000 b 
31,000 b 
21,500 b 
<LC 
0 14 22 42 57 92 103 95 
% activity 
(B) Rl55A-Meizothrombin 
J hFV 
-280,000 
220,000 
200.000 D 
116,500 D -HC 
97,400 D 
66,200 D 
45,000 D 
31,000 D 
21,000 b 
<LC 
0 12 22  29 41 70 88 100 
% activity 
FIG. 4. Gel electrophoretic analysis of  factor V act ivat ion  by 
thrombin  and R155A meizothrombin.  Human factor  V (hFV, 365 
nM) was  activated at  37 "C with  2.5 nsl thrombin (A)  or R155A meizo- 
thrombin ( B )  in  a  reaction  mixture  containing  25 mh1 Hepes  (pH 7.5L 
175 mM NaCI, 5 mM CaCI,, and 60 p~ DOPSlDOPC (10:90 moVmo1) 
vesicles. After different time intervals, aliquots from the activation 
mixture  were  assayed for the presence of factor Va as described  under 
"Experimental  Procedures."  At the  same  times,  10-pl  aliquots from the 
activation  mixture  were mixed with  10 pl of SDS- and mercaptoethanol- 
containing  gel buffer. To allow correlation of activation with product 
formation, the gel represents SDS-PAGE analysis of samples  that  are 
matched  as closely as  possible with  respect  to the factor Va activities 
generated  in  the  reaction  mixtures. HC and LC, heavy  and  light  chains 
of factor Va, respectively. 
equation  and yielded a rate  constant  equal  to  that calculated 
from the  initial  rate of factor Va formation. However, the  time 
course of R155Ameizothrombin-catalyzed activation of factor  V 
(Fig. 2B) did not  adhere  to  the  equation for a pseudo first-order 
reaction. The  experimental  curve  was biphasic, with a rapid 
initial  phase (60% of the  reaction) followed  by a slower second 
phase  that completes  factor  V  activation.  Possible explanations 
for this biphasic  behavior are given under "Discussion." 
SDS-PAGE  Analysis of Factor VActivation by Thrombin  and 
R155A Meizothrombin-Generation of reaction intermediates 
and products during factor V activation by thrombin and 
R155A meizothrombin was  analyzed by  SDS-PAGE (Fig. 4, A 
and B) .  In  agreement  with  the  literature (1-61, thrombin-cata- 
lyzed activation of factor V proceeds via the  characteristic high 
molecular weight  intermediates of 280,000 and 220,000. The 
M, 280,000 intermediate  was, however, hardly formed when 
factor V was  activated by R155A meizothrombin  (Fig. 4B). This 
indicates differences in  either  the  order or the  rate of peptide 
bond cleavage during factor  V  activation by thrombin  or R155A 
meizothrombin. Further processing of the  high molecular 
weight  intermediates  resulted  in both  cases in  the  generation of 
activation  fragments, which were hardly visible on the gel due 
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15972 Factor V Activation by Meizothrombin 
to poor staining  with Coomassie Blue (5), and  in  the formation 1 2  3 
of a factor Va molecule that consisted of a heavy  chain  with an 
M, of 104,000 and a light  chain doublet with M ,  values of 74,000 
and 71,000. 
DISCUSSION 
Factor V activation is an important reaction in  hemostatic 
plug formation. It results  in  the  formation of factor Va, the 
protein cofactor that  greatly  accelerates  prothrombin  activa- 
tion  and  that  regulates  the  rate of thrombin formation. Factor 
V is  rapidly  activated by thrombin (1-6) and by factor Xa (6), 
which are  the  proteases  that  are  generally considered to be the 
physiological activators of factor V. 
In  this  paper, we report that factor V is also readily  activated 
by meizothrombin, provided that negatively charged mem- 
branes  are  present  as a catalytic surface.  Meizothrombin is a 
reaction intermediate  that  accumulates  in  the  early  phase of 
prothrombin  activation a t  concentrations  that exceed those of 
thrombin (12-15). Meizothrombin is a serine protease that, 
compared with  thrombin,  was  reported  to  exhibit  greatly  re- 
duced activity toward macromolecular thrombin substrates 
such as fibrinogen (12, 161, platelets (161, and  factor V (16). 
Evaluation of the  catalytic  activity of meizothrombin is, how- 
ever, hampered by the  fact  that it is  further processed into 
meizothrombin(desF1) (fast)  or  a-thrombin (slow) (12, 17)  via 
an autocatalytic reaction. Removal of the  F1 domain, which 
contains  the y-carboxyglutamic  acid residues  that function in 
the binding of meizothrombin to procoagulant membranes, 
may especially influence those catalytic activities of meizo- 
thrombin  that  may occur on a phospholipid surface, e.g. protein 
C and/or  factor V  activation. To enable activity studies of meizo- 
thrombin, we have  prepared a recombinant  human  prothrom- 
bin in which Arg155 is replaced by Ala. The  recombinant pro- 
thrombin  was converted into a meizothrombin derivative 
(R155A meizothrombin) that is resistant  to  autocatalytic  re- 
moval of the F1 domain. In  free solution,  R155Ameizothrombin 
is a poor activator of factor  V and  activates  factor V at a rate 
that  is <2%  of that of thrombin (k = 0.06 x lo6 versus 4.0 x lo6 
M - ~  s-'). However, when negatively charged phospholipid 
vesicles are included in  the reaction mixture,  there is a phos- 
pholipid-dependent increase  in  the  rate of R155A meizothrom- 
bin-catalyzed factor V activation,  reaching a plateau  value  with 
an average  activation  rate  constant of k = 19 x lo6 M-, s-, at 250 
p~ PSPC. Since activation of factor  V by thrombin or meizo- 
thrombin(desF1) is hardly affected by the presence of phospho- 
lipid, we conclude that  the  stimulation  in  the  case of R155A 
meizothrombin is due  to  the  fact  that  both  the  enzyme (R155A 
meizothrombin) and  the  substrate (factor V) bind  to  the mem- 
brane surface. This  simultaneous  binding promotes the  inter- 
action between two poorly interacting components (R155A 
meizothrombin and factor V), which results  in  an  increased 
rate of factor V activation.  Such a mechanism of action of mem- 
branes  has also been proposed for other phospholipid-depend- 
ent coagulation  factor activations (23). 
The  final product of both  thrombin-  and R155A meizothrom- 
bin-catalyzed activation of factor  V is a factor Va molecule that 
consists of the  characteristic  heavy  and  light  chains.  There  are, 
however, some differences in the pattern of high molecular 
weight intermediate  generation  in  the  early  phase of the  acti- 
vation reaction. Gel electrophoretic analysis  (Fig.  4) shows that 
thrombin  activates  factor V via M, 280,000 and 220,000 inter- 
mediates  (designated A, and B in Ref. 1) by successive  cleavage 
of peptide bonds 1-3 (Fig. 5). The M, 280,000 intermediate  is, 
however, hardly formed during  factor V activation by R155A 
meizothrombin. This indicates that, under these conditions, 
there is a change  in  either  the  rate  or  the  order of p ptide bond 
cleavages during factor V activation. Such an effect may be 
specific for situations  in which membrane-bound  factor V is 
4 4  4 
C- 280 kD - 
C- 220 kD- 
"C i i LC I 
FIG. 5. Peptide bonds cleaved by thrombin during factor V ac- 
tivation. HC and LC, heavy and light chains of factor Va, respectively. 
activated by a membrane-bound  enzyme since a similar  acti- 
vation  pattern (i.e. reduced M, 280,000 intermediate  formation) 
was also  observed in the case of phospholipid-dependent acti- 
vation of factor V by factor Xa (6).  A  phenomenon like  this  may 
be caused by a steric or juxtaposing effect that  results from 
coordinate binding of substrate  and enzyme to  the  membrane 
surface. 
The  observations that meizothrombin-catalyzed factor V  ac- 
tivation occurs at a membrane  surface  via a peptide bond cleav- 
age pattern that differs from that of factor V activation by 
thrombin  may explain why time courses of factor Va formation 
are  biphasic  in  the cas  of meizothrombin and monophasic in  the 
case of thrombin. Recently, we reported  that factor  V prepara- 
tions  contain two forms of factor  V with different  affinities  for 
negatively charged  membranes (18).Although there  may be sev- 
eral  explanations for biphasic time courses of product genera- 
tion  during pseudo first-order  reactions, we would like  to  men- 
tion two possibilities that  relate  to  the  observations mentioned 
above: 1) fast  generation of an activation  intermediate  with a 
cofactor activity  that is lower than  that of a slowly formed end 
product  (factor Va) or 2) fast  activation of the  factor V that  binds 
with high affinity to  phospholipid, followed  by slow activation of 
the  factor V molecules that  have a low affinity for phospholipid. 
The  data  presented  in this paper show that meizothrombin is 
a potent  factor V activator  in  the presence of phospholipids. The 
rate  constant for R155A meizothrombin-catalyzed factor V ac- 
tivation (18 x lo6 M-' s-') even exceeds those determined for 
activation by thrombin  (4 x lo6 M - ~  s-'; this  paper  and Ref. 6) and 
factor Xa (3.26 x lo6 M" s-'; Ref. 6).  Since the first prothrombin 
molecules that are  activated  during coagulation in whole blood 
are likely  converted into meizothrombin (151, meizothrombin 
should be  considered as a physiologically important factor V 
activator  with a major  function during  the  phase of coagulation 
in which the  prothrombinase complex is generated. 
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